ANDA Reformulations Should Not Result In Loss Of 180-Day Exclusivity - Andrx

Reformulation of a product under ANDA review should not result in the loss of 180-day exclusivity eligibility, Andrx argued in Oct. 5 comments to FDA's 180-day generic exclusivity proposed rule.